CNR Research Posts Record CRO Order Backlog as Overseas Contracts and AI Platform Transition Drive Growth

• CNR Research, South Korea’s first full-cycle CRO, has reached a record-high order backlog — estimated to represent approximately three years of revenue visibility — after new orders in the first half of 2026 alone exceeded the company’s full-year 2025 order value of 53.2 billion won, driven by accelerating global project wins in the United States and Southeast Asia.

• Analysis by independent research firm ARIS identifies three structural growth drivers: continued expansion of global clinical trial contracts including high-value U.S. oncology, ADC, and biosimilar programs; a strategic transition toward an AI-based data CRO platform; and entry into the real-world data and evidence market following the acquisition of Mediplexus — positioning CNR Research for a potential corporate value re-rating.

CNR Research, South Korea’s first contract research organization and a full-cycle CRO serving pharmaceutical companies and biotech ventures, has reached a record-high order backlog, according to analysis published on July 7, 2026 by independent research firm ARIS. New orders secured in the first half of 2026 are estimated to have exceeded the company’s full annual order value of 53.2 billion won recorded in 2025, with global project orders reaching approximately 18.3 billion won — reflecting a significant acceleration in international CRO demand for CNR Research’s services. ARIS estimates the company currently holds approximately three years of revenue visibility.

The geographic composition of CNR Research’s global order intake highlights two distinct expansion corridors. In the United States, the company is executing high-value programs in oncology, antibody-drug conjugates, and biosimilars — therapeutic and modality categories where clinical trial complexity, regulatory scrutiny, and the need for experienced CRO partners are all elevated. In Southeast Asia, CNR Research has established operations across Thailand, Indonesia, and Vietnam, markets that ARIS identified as offering cost competitiveness and patient recruitment efficiency advantages relative to more established clinical trial geographies. The company’s contract with Daewoong Pharmaceutical for a global Phase 3 clinical trial was cited by ARIS as a demonstration of CNR Research’s capacity to execute at the highest level of international clinical development.

A strategic transition toward an AI-based data CRO platform is the second axis of CNR Research’s growth thesis. The company is integrating AI across the entire clinical trial process — from design and data management through regulatory approval support — with the objective of shifting from a labor-intensive operating model toward a scalable, platform-based structure. This transition is positioned as a long-term differentiator, improving both operational efficiency and the quality and speed of data outputs for sponsors. Alongside the AI initiative, CNR Research’s acquisition of Mediplexus has extended its service scope into real-world data and real-world evidence, broadening its addressable market into post-approval drug development services and pharmacovigilance support.

ARIS forecast CNR Research will record revenue of 70 billion won and operating profit of 4.5 billion won in 2026, with the company entering a more sustained growth phase from the second half of the year as order growth and profitability improvement converge. CNR Research provides full-cycle clinical trial services covering clinical design, data management, and regulatory approval support, and has been building its international presence at a time of growing global demand for Asian CRO partners with demonstrated multinational execution capability.

“CNR Research is in a phase where global clinical trial expansion and a shift to an AI-based business structure are progressing simultaneously. As order growth and profitability improvement come together, there is potential for a re-rating of its corporate value.”

ARIS, the organizations stated